Market News & Trends
Nxera Pharma to Receive $4.6 Million in Milestone Payments Rrom Centessa Pharmaceuticals
Nxera Pharma recently announced it expects to receive $4.6 million in milestone payments from Centessa Pharmaceuticals pursuant to a license agreement regarding Nxera technology used…
Jeito Capital Announces Acquisition by Merck & Co. of its Portfolio Company EyeBio for a Potential Value of $3 Billion
This acquisition reflects the significant clinical progress achieved with Restoret, EyeBio’s novel late-phase candidate for diabetic macular edema, as well as….
Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment
Skinvisible Pharmaceuticals, Inc. recently announced a major advancement in the battle against obesity. The company has achieved a significant milestone by officially filing a provisional patent application covering formulations that….
Vyluma Announces Marketing Authorization Application Validation for the European Union
Vyluma, Inc. recently announced the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for its lead compound, NVK002. The application is confirmed…
BioNTech & CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
BioNTech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) are expanding their strategic partnership to contribute to building a sustainable and resilient end-to-end African vaccine…
Evonik Drives Sustainable Biosurfactant Revolution With Inauguration of New Facility in Slovakia
First facility worldwide to manufacture industrial-scale rhamnolipid biosurfactants; huge potential in personal care, cleaning, coatings, animal nutrition, agriculture, and many other applications….
Bluejay Therapeutics Receives Positive Opinion on Orphan Designation From the EMA for the Treatment of Chronic Hepatitis D
Bluejay Therapeutics recently announced the European Medicines Agency (EMA) has issued a positive opinion on the company’s application for orphan designation for BJT-778 for the…
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
ProBioGen recently announced a pivotal collaboration with ModeX Therapeutics an OPKO Health Company dedicated to combating cancer and infectious diseases with cutting-edge….
Kindeva Global Health Security Donates ATNAA to Ukraine Through the European Commission’s rescEU & Governmental Strategic Reserves Agency (RARS)
Kindeva Drug Delivery recently announced it donated a supply of autoinjectors — specifically an antidotal treatment for chemical nerve agents — to Ukraine through the…
RespireRx Announces DoD Award to Fund Phase 2 Clinical Study to Determine Safety & Efficacy of its Lead AMPAkine to Improve Bladder Function in Patients With Spinal Cord Injury
RespireRx Pharmaceuticals Inc. recently announced the Department of Defense (DoD) has approved a $1.8-million translational research award to Shirley Ryan AbilityLab to fund a two-stage…
Artelo Biosciences Presents Highly Encouraging Data Toward Developing Solid Dosage Form of ART12.11
Artelo Biosciences, Inc. recently announced Dr. Andrew Yates presented new preclinical data on ART12.11 at the CT-CANN24 conference held May 29-30, 2024, at the Hilton…
Spinogenix Announces FDA Clearance of IND Application Novel Therapy for the Treatment of ALS
Spinogenix, Inc. recently announced the US FDA has cleared the Investigational New Drug (IND) application for its Phase 1/2 clinical trial of SPG302 for the…
Oncovita & Institut Pasteur Announce Creation of Joint Laboratory Dedicated to Cancer Immunotherapy & Prophylactic Vaccinology
Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the joint Institut Pasteur - Oncovita laboratory is aimed…
Secarna Pharmaceuticals & Orbit Discovery Enter Collaboration to Discover & Develop Peptide-Conjugated Targeted Antisense Oligonucleotide Therapeutics
New platform capabilities extend the reach of Secarna’s antisense approaches, potentially offering new treatment options for a wider range of diseases….
Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare Company
Asahi Kasei Corp. recently announced it will offer the shareholders of Calliditas Therapeutics AB to acquire the shares of the pharmaceutical company Calliditas for the purpose of….
selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients With Psoriasis Vulgaris or Psoriatic Arthritis
selectION, Inc. recently announced the initiation of a Phase 1b trial with its lead compound si-544 in adult patients with psoriasis vulgaris (Ps) or psoriatic…
Agios Announces $905-Million Purchase Agreement for Vorasidenib Royalty
Agios Pharmaceuticals, Inc. recently announced it has agreed to sell its rights to its 15% royalty on potential US net sales of Servier’s vorasidenib to….
GlycoNex & PrecisemAb Sign Technology Licensing Agreement to Advance Development of Novel Anti-Glycan Antibodies for Cancer Therapy
GlycoNex to advance development of novel pro-antibody cancer drugs that enhance tumor suppression while minimizing off-site binding to healthy tissues to improve safety and tolerability….
CARGO Therapeutics Announces $110-Million Private Placement Equity Financing
CARGO Therapeutics, Inc. recently announced it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to…
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism
Corcept Therapeutics Incorporated recently announced that GRACE, the Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism (Cushing’s syndrome), met…
